Trial results for a study investigating continuous glucose monitoring (CGM) in Type 2 Diabetes patients were posted on ClinicalTrials.gov on 2025-12-09, reporting a mean increase of 8.51% in Time in Range (TIR) with a p-value of 0.03.
Background
Type 2 Diabetes is a chronic metabolic condition characterized by high blood sugar. For insulin-requiring patients, particularly after hospitalization, maintaining glycemic control is crucial to prevent complications and readmissions. Continuous glucose monitoring (CGM) systems offer real-time glucose data, which can empower patients and providers to make timely adjustments to treatment. This observational study explored the utility of CGM in this specific patient population following hospital discharge.
Trial design
This observational cohort study, designated as Phase NA, enrolled 108 participants with Type 2 Diabetes. The study focused on hospitalized insulin-requiring patients who received a Dexcom continuous glucose monitor (CGM) to wear for 12 weeks post-hospital discharge. Participants completed surveys, and CGM data was captured for analysis. The study aimed to assess the impact of CGM use in this population, providing personalized glucose targets and alerts, and sending customized reports to their diabetes providers.
Key results
The study reported several key measurements and analyses related to CGM use:
- For the Dexcom CGM group, the mean change in Time in Range (TIR) 70-180 mg/dl was 8.5 percentage points (Standard Deviation 28).
- 54 participants achieved a wear time greater than 70%.
- The median DTSQc Score was 8 on a scale.
Key analyses included:
- A paired t-test comparing the %Time in Range from 2 weeks to 12 weeks showed a mean difference (net) of 8.51, with a p-value of 0.03.
- A paired Wilcoxon rank test yielded a Wilcoxon signed rank value of 9.85, with a p-value of 0.0001.
What this means
The results suggest that continuous glucose monitoring following hospital discharge may contribute to improved glycemic control in insulin-requiring Type 2 Diabetes patients. The statistically significant increase in Time in Range, as indicated by the paired t-test (p=0.03), highlights a potential benefit of CGM in helping patients manage their glucose levels more effectively. The reported high percentage of wear time also indicates good patient adherence to CGM use in this cohort, which is crucial for its effectiveness.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05360056, titled "Continuous Glucose Monitoring Following Hospital Discharge", were posted on 2025-12-09 on clinicaltrials.gov.